Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Malignant Lymphoma

Free Subscription 23.01.2023 1 Am J Hematol 2 Blood 2 Cancer 4 Eur J Haematol 1 Haematologica 1 J Clin Oncol 3 Leuk Lymphoma 1 Leukemia 1 Oncol Rep

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. LASATER EA, Amin DN, Bannerji R, Mali RS, et al
   Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R NHL: Results from preclinical models and a Phase Ib study.
   Am J Hematol. 2023 Jan 2. doi: 10.1002/ajh.26809.
   PubMed         Abstract available
   
   

   
   Blood

2. YUAN CT, Chuang SS
   Effusion presentation of HHV-8-associated multicentric Castleman disease mimicking primary effusion lymphoma.
   Blood. 2023;141:320.
   PubMed        
   
   
3. SCHLAPBACH C
   TOXic T-cell cytokines wreak havoc in CTCL skin.
   Blood. 2023;141:127-128.
   PubMed        
   
   

   
   Cancer

4. ALLEN PB, McCook-Veal AA, Switchenko JM, Paulino DM, et al
   Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study.
   Cancer. 2023;129:541-550.
   PubMed         Abstract available
   
   
5. BODDU PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, et al
   A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
   Cancer. 2023;129:580-589.
   PubMed         Abstract available
   
   

   
   Eur J Haematol

6. TEY A, Schwarer J, Raffa R, Shi E, et al
   High risk of infection in 'real-world' patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma.
   Eur J Haematol. 2023 Jan 19. doi: 10.1111/ejh.13928.
   PubMed         Abstract available
   
   
7. ELLIOTT EK, Hensen R, Haupt LM, Griffiths LR, et al
   Global reported impacts of COVID-19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic.
   Eur J Haematol. 2023 Jan 19. doi: 10.1111/ejh.13926.
   PubMed         Abstract available
   
   
8. YUE X, Hallett D, Liu Y, Basa E, et al
   Outcomes of coronavirus disease 2019 (COVID-19) and risk factors associated with severe COVID-19 in patients with mature B-cell non-Hodgkin lymphomas: A US electronic health record cohort study.
   Eur J Haematol. 2023;110:177-187.
   PubMed         Abstract available
   
   
9. SHARGIAN L, Amit O, Bernstine H, Gurion R, et al
   The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission-A retrospective multicenter study.
   Eur J Haematol. 2023;110:149-156.
   PubMed         Abstract available
   
   

   
   Haematologica

10. DI M, Long JB, Kothari SK, Sethi T, et al
    Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis.
    Haematologica. 2023 Jan 19. doi: 10.3324/haematol.2022.282252.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

11. GROMMES C
    Circulating Tumor DNA in the Blood: A New Frontier in Primary CNS Lymphoma?
    J Clin Oncol. 2023 Jan 20:JCO2202605. doi: 10.1200/JCO.22.02605.
    PubMed        
    
    

    
    Leuk Lymphoma

12. LIN M, Wu X, Zhang L, Li L, et al
    Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma.
    Leuk Lymphoma. 2023 Jan 19:1-8. doi: 10.1080/10428194.2023.2167492.
    PubMed         Abstract available
    
    
13. GAUT D, Oliai C, Mead M
    Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series.
    Leuk Lymphoma. 2023 Jan 17:1-4. doi: 10.1080/10428194.2022.2151839.
    PubMed        
    
    
14. QUALLS D, Noy A, Straus D, Matasar M, et al
    Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.
    Leuk Lymphoma. 2023 Jan 15:1-4. doi: 10.1080/10428194.2022.2164194.
    PubMed        
    
    

    
    Leukemia

15. CHIAPPELLA A, Dodero A, Evangelista A, Re A, et al
    Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study.
    Leukemia. 2023 Jan 18. doi: 10.1038/s41375-022-01780.
    PubMed         Abstract available
    
    

    
    Oncol Rep

16. XING X, Liu M, Wang X, Guo Q, et al
    Promoting effects of calponin 3 on the growth of diffuse large B‑cell lymphoma cells.
    Oncol Rep. 2023;49:46.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: